Europa Trial
Home
Sitemap
General Public Heathcare Professionals Virtual Press Office

New Indication in CAD

EUROPA calendar
ACC 2006 - Posters
ESC 2005 - Symposium
ESC 2005 - Oral sessions
ESC 2005 - Posters
AHA 2004 - Oral Session
ESC 2004 - Hotline
ESC 2004 - Symposium
ACC 2004
ESC 2003


EUROPA study
EUROPA Results
ESC 2003 Hotline - video
Rationale for EUROPA
Rationale for Perindopril
Design & Organisation
EUROPA investigators
EUROPA collaborating centres
EUROPA Recruitment


EUROPA Slide Set
Rationale and Design
Results
Clinical Implications


EUROPA publications


PERSUADE
PERSUADE Publications
PERSUADE Results
PERSUADE Fact Sheet


PERTINENT
PERTINENT Results
PERTINENT Fact Sheet


Background : Coronary Artery Disease
Home : Healthcare professionals : ESC 2005 - Symposium
ESC 2005 - Symposium

     

SECONDARY PREVENTION OF CORONARY ARTERY DISEASE:
THE ESTABLISHED ROLE OF PERINDOPRIL


Stockholm (Sweden)
Monday September 5, 2005 (18.30-20.00)

European Society of Cardiology Congress – Stockholm (Sweden)



* The EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease

Chairpersons:
J.P. Bassand (France) – H. Dargie (UK)

Introduction: H. Dargie (UK)
Specificity of inhibiting the renin angiotensin aldosterone system with perindopril
R. Ferrari (Italy)
Prevention of events in coronary artery disease patients with ACE inhibitors: new insights from EUROPA
K. Fox (UK)
Rationale and design of the PREAMI study: a randomised trial in patients with myocardial infarction and preserved ejection fraction
L. Tavazzi (Italy)
Effects of perindopril on remodeling in elderly patients with acute myocardial infarction: the PREAMI results
W.J. Remme (Netherlands)
From acute myocardial infarction to secondary prevention: evidence for benefits of perindopril in coronary artery disease patients
M. Bertrand (France)
Conclusion: J. P. Bassand (France)


14 minutes for each talk followed by a 3-minute discussion


This website is intended for an international audience. Drug related information may refer to unlicensed products or uses which may not be approved in your own country and you should therefore consult your local prescribing information.
This site is published and updated by the EUROPA study investigators. Site last updated March 21st 2006
To report a suspected side-effect with a Servier drug, please click here.
Terms of use - ©2005 EUROPA All rights reserved